Antiinflammatory cell adhesion inhibitors
AssigneeGlycorex AB
InventorsCarlo Unverzagt, Gregor Kuznik, Gerhard Kretzschmar
Life of this patent
Estimating the term…
Abstract
The invention relates to compounds of formula Ix and Ia: ##STR1## wherein (Ix) comprises the regioisomeric form sLe.sup.X and (Ia) comprises the regioisomeric form sLe.sup.A, and R.sup.1 is a lipophilic radical formed from aliphatic or cycloaliphatic units, or a sugar residue which is capped by a .beta.1-O-linked aliphatic or cycloaliphatic unit at the reducing end of the terminal sugar. The compounds of the present invention are useful as inhibitors of increased cell-cell adhesion as well as useful in treating diseases associated with increased cell-cell-adhesion. The compounds of the present invention are also incorporated into pharmaceutical compositions.
Claims17
A compound selected from the group consisting of:
- ##STR7## wherein NeuNH.sub.2 is 5-aminoneuraminic acid, and Glc(NH.sub.2) is 2-amino-2-deoxyglucose, and
- R.sup.1 is a lipophilic radical formed from aliphatic or cycloaliphatic units, or a sugar residue which is capped by a .beta.1-O-linked aliphatic or cycloaliphatic unit at the reducing end of the terminal sugar.
A compound selected from the group consisting of:
- ##STR9## wherein NeuNH.sub.2 is 5-aminoneuraminic acid, and Glc(NH.sub.2) is 2-amino-2-deoxyglucose, and
- R.sup.1 is a lipophilic radical formed from aliphatic units, or a monosaccharide sugar residue which is capped by a .beta.1-O-linked aliphatic or cycloaliphatic unit at the reducing end of the terminal sugar.
A process for preparing a carbohydrate selectin receptor blocker comprising treating an oligosaccharide with base wherein said oligosaccharide comprises a sialic acid moiety and a N-acetylglucosamine moiety whereby the sialic acid moiety and the N-acetylglucosamine moiety of the oligosaccharide are deacetylated.
Dependencies are inferred from the claim text.